These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21212150)

  • 21. Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in Klebsiella pneumoniae and Escherichia coli.
    Klontz EH; Tomich AD; Günther S; Lemkul JA; Deredge D; Silverstein Z; Shaw JF; McElheny C; Doi Y; Wintrode PL; MacKerell AD; Sluis-Cremer N; Sundberg EJ
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated Expression of GlpT and UhpT via FNR Activation Contributes to Increased Fosfomycin Susceptibility in Escherichia coli under Anaerobic Conditions.
    Kurabayashi K; Tanimoto K; Fueki S; Tomita H; Hirakawa H
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6352-60. PubMed ID: 26248376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
    Mikuniya T; Kato Y; Ida T; Maebashi K; Monden K; Kariyama R; Kumon H
    J Infect Chemother; 2007 Oct; 13(5):285-90. PubMed ID: 17982715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Surviving Forms in Antibiotic-Treated Pseudomonas aeruginosa].
    Mulyukin AL; Kozlova AN; Sorokin VV; Suzina NE; Cherdyntseva TA; Kotova IB; Gaponov AM; Tutel'yan AV; El'-Registan GI
    Mikrobiologiia; 2015; 84(6):645-59. PubMed ID: 26964354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
    Rodríguez-Rojas A; Couce A; Blázquez J
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4948-9. PubMed ID: 20713658
    [No Abstract]   [Full Text] [Related]  

  • 27. Pseudomonas aeruginosa
    Van Laar TA; Esani S; Birges TJ; Hazen B; Thomas JM; Rawat M
    mSphere; 2018 Apr; 3(2):. PubMed ID: 29669887
    [No Abstract]   [Full Text] [Related]  

  • 28. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
    Epstein SP; Bottone EJ; Asbell PA
    Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates.
    Pasca MR; Dalla Valle C; De Jesus Lopes Ribeiro AL; Buroni S; Papaleo MC; Bazzini S; Udine C; Incandela ML; Daffara S; Fani R; Riccardi G; Marone P
    Microb Drug Resist; 2012 Feb; 18(1):23-32. PubMed ID: 21797666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial Susceptibility and Molecular Mechanisms of Fosfomycin Resistance in Clinical Escherichia coli Isolates in Mainland China.
    Li Y; Zheng B; Li Y; Zhu S; Xue F; Liu J
    PLoS One; 2015; 10(8):e0135269. PubMed ID: 26252888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.
    Pruekprasert P; Tunyapanit W
    Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1239-42. PubMed ID: 16438151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.
    Pan AJ; Mei Q; Ye Y; Li HR; Liu B; Li JB
    J Antibiot (Tokyo); 2017 Feb; 70(2):166-173. PubMed ID: 27756910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
    Li Bassi G; Motos A; Fernandez-Barat L; Aguilera Xiol E; Chiurazzi C; Senussi T; Saco MA; Fuster C; Carbonara M; Bobi J; Amaro R; De Rosa F; Comaru T; Yang H; Ranzani OT; Marti JD; Rinaudo M; Comino Trinidad O; Rigol M; Bringué J; Ramirez J; Nicolau DP; Pelosi P; Antonelli M; Blasi F; Artigas A; Montgomery AB; Torres A
    Crit Care Med; 2019 Jun; 47(6):e470-e477. PubMed ID: 30882478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between sensitivity to fosfomycin and the presence of penicillinase PSE-1 in Pseudomonas aeruginosa].
    Hance P; Fabre R; Leblanc F; Cavallo JD
    Pathol Biol (Paris); 2001 Feb; 49(1):12-5. PubMed ID: 11265218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxygen Limitation Enhances the Antimicrobial Activity of Fosfomycin in
    Hirakawa H; Kurabayashi K; Tanimoto K; Tomita H
    Front Microbiol; 2018; 9():1950. PubMed ID: 30186264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lethal Effect of Photodynamic Treatment on Persister Bacteria.
    Oppezzo OJ; Forte Giacobone AF
    Photochem Photobiol; 2018 Jan; 94(1):186-189. PubMed ID: 28881420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa].
    Gómez-Garcés JL; Gil-Romero Y; Sanz-Rodríguez N; Muñoz-Paraíso C; Regodón-Domínguez M
    Enferm Infecc Microbiol Clin; 2016 Apr; 34(4):228-31. PubMed ID: 26277206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
    Paladino JA; Sunderlin JL; Forrest A; Schentag JJ
    J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant
    Olivares Pacheco J; Alvarez-Ortega C; Alcalde Rico M; Martínez JL
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.